153 related articles for article (PubMed ID: 38707478)
1. The predictive value of serum tumor markers for EGFR mutation in non-small cell lung cancer patients with non-stage IA.
Du W; Qiu T; Liu H; Liu A; Wu Z; Sun X; Qin Y; Su W; Huang Z; Yun T; Jiao W
Heliyon; 2024 May; 10(9):e29605. PubMed ID: 38707478
[TBL] [Abstract][Full Text] [Related]
2. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
Wang S; Ma P; Ma G; Lv Z; Wu F; Guo M; Li Y; Tan Q; Song S; Zhou E; Geng W; Duan Y; Li Y; Jin Y
Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
[TBL] [Abstract][Full Text] [Related]
3. Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of
Jiang M; Chen P; Guo X; Zhang X; Gao Q; Zhang J; Zhao G; Zheng J
EJNMMI Res; 2023 Apr; 13(1):27. PubMed ID: 37014455
[TBL] [Abstract][Full Text] [Related]
4. Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy.
Chen Z; Liu L; Zhu F; Cai X; Zhao Y; Liang P; Ou L; Zhong R; Yu Z; Li C; Li J; Xiong S; Feng Y; Cheng B; Liang H; Xie Z; Liang W; He J
Cancer Med; 2022 Aug; 11(16):3115-3125. PubMed ID: 35543090
[TBL] [Abstract][Full Text] [Related]
5. Nomogram based on clinical characteristics and radiological features for the preoperative prediction of spread through air spaces in patients with clinical stage IA non-small cell lung cancer: a multicenter study.
Wang Y; Lyu D; Zhang D; Hu L; Wu J; Tu W; Xiao Y; Fan L; Liu S
Diagn Interv Radiol; 2023 Nov; 29(6):771-785. PubMed ID: 37724737
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
Jiang R; Wang X; Li K
Oncotarget; 2016 May; 7(18):26823-36. PubMed ID: 27072585
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
9. Value of combining serum carcinoembryonic antigen and PET/CT in predicting
Gu J; Xu S; Huang L; Li S; Wu J; Xu J; Feng J; Liu B; Zhou Y
J Thorac Dis; 2018 Feb; 10(2):723-731. PubMed ID: 29607142
[TBL] [Abstract][Full Text] [Related]
10. Relationship between serum carcinoembryonic antigen level and epidermal growth factor receptor mutations with the influence on the prognosis of non-small-cell lung cancer patients.
Cai Z
Onco Targets Ther; 2016; 9():3873-8. PubMed ID: 27390527
[TBL] [Abstract][Full Text] [Related]
11. Value of serum tumor markers for predicting EGFR mutations in non-small cell lung cancer patients.
Wen L; Wang S; Xu W; Xu X; Li M; Zhang Y; Du X; Liu S
Ann Diagn Pathol; 2020 Dec; 49():151633. PubMed ID: 32977235
[TBL] [Abstract][Full Text] [Related]
12. Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study.
Tan X; Li Y; Wang S; Xia H; Meng R; Xu J; Duan Y; Li Y; Yang G; Ma Y; Jin Y
Respir Res; 2022 May; 23(1):132. PubMed ID: 35624472
[TBL] [Abstract][Full Text] [Related]
13. [Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].
Wang Q; Zheng H; Hu F; Zhang H; Hu Y; Li J; Zhang T; Liu Z; Lu B; Hu A; Li B
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):550-8. PubMed ID: 27561807
[TBL] [Abstract][Full Text] [Related]
14. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
15. [Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKI in advanced non-small cell lung cancer harboring EGFR mutations].
Jin B; Zhang Y; Zhang X; Li R; Lou Y; Niu Y; Huang A; Han B
Zhonghua Yi Xue Za Zhi; 2014 Aug; 94(30):2327-31. PubMed ID: 25399971
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a nomogram to assess postoperative venous thromboembolism risk in patients with stage IA non-small cell lung cancer.
Cai Y; Dong H; Li X; Liu Y; Hu B; Li H; Miao J; Chen Q
Cancer Med; 2023 Jan; 12(2):1217-1227. PubMed ID: 35758614
[TBL] [Abstract][Full Text] [Related]
17. Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations.
Dong J; Tong S; Shi X; Wang C; Xiao X; Ji W; Sun Y
Cancer Manag Res; 2020; 12():13607-13616. PubMed ID: 33447080
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive value of serum carcinoembryonic antigen levels in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutations and receiving tyrosine kinase inhibitors.
Zhao XM; Zhao J; Xing KL; Sun S; Luo ZG; Wang HJ; Wang JL; Chang JH; Wu XH
Oncotarget; 2017 Sep; 8(41):70865-70873. PubMed ID: 29050327
[TBL] [Abstract][Full Text] [Related]
19. Establishment and Evaluation of EGFR Mutation Prediction Model Based on Tumor Markers and CT Features in NSCLC.
Zhang H; He M; Wan R; Zhu L; Chu X
J Healthc Eng; 2022; 2022():8089750. PubMed ID: 35422977
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the application value of seven tumor-associated autoantibodies in non-small cell lung cancer based on machine learning algorithms].
Hao Y; Wu LN; Lyu YT; Liu YZ; Qin XS; Zheng R
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Nov; 57(11):1827-1838. PubMed ID: 38008573
[No Abstract] [Full Text] [Related]
[Next] [New Search]
